Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes.

Cullinane C, Deacon GB, Drago PR, Erven AP, Junk PC, Luu J, Meyer G, Schmitz S, Ott I, Schur J, Webster LK, Klein A.

Dalton Trans. 2018 Feb 6;47(6):1918-1932. doi: 10.1039/c7dt04615d.

PMID:
29340396
2.

Systematic differences in electrochemical reduction of the structurally characterized anti-cancer platinum(IV) complexes [Pt{((p-HC6F4)NCH2)2}-(pyridine)2Cl2], [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)2], and [Pt{((p-HC6F4)NCH2)2}(pyridine)2(OH)Cl].

Guo SX, Mason DN, Turland SA, Lawrenz ET, Kelly LC, Fallon GD, Gatehouse BM, Bond AM, Deacon GB, Battle AR, Hambley TW, Rainone S, Webster LK, Cullinane C.

J Inorg Biochem. 2012 Oct;115:226-39. doi: 10.1016/j.jinorgbio.2012.07.016. Epub 2012 Jul 27.

PMID:
22921430
3.

Preparation and Anti-Tumour Activity of Some Arylbismuth(III) Oxine Complexes.

Smith KA, Deacon GB, Jackson WR, Tiekink ER, Rainone S, Webster LK.

Met Based Drugs. 1998;5(5):295-304. doi: 10.1155/MBD.1998.295.

4.

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.

Ellis AG, Doherty MM, Walker F, Weinstock J, Nerrie M, Vitali A, Murphy R, Johns TG, Scott AM, Levitzki A, McLachlan G, Webster LK, Burgess AW, Nice EC.

Biochem Pharmacol. 2006 May 14;71(10):1422-34. Epub 2006 Mar 7.

PMID:
16522318
5.

Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.

Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW, Russell PJ.

Gene Ther. 2004 Nov;11(21):1559-67.

PMID:
15343359
6.

A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy.

Loi S, Rischin D, Michael M, Yuen K, Stokes KH, Ellis AG, Millward MJ, Webster LK.

Cancer Chemother Pharmacol. 2004 Nov;54(5):407-14. Epub 2004 Jul 3.

PMID:
15235821
7.

The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe.

Ilinski P, Lai B, Cai Z, Yun W, Legnini D, Talarico T, Cholewa M, Webster LK, Deacon GB, Rainone S, Phillips DR, Stampfl AP.

Cancer Res. 2003 Apr 15;63(8):1776-9.

9.

Synthesis, cytotoxicity, cell uptake and DNA interstrand cross-linking of 4,4'-dipyrazolylmethane-linked multinuclear platinum anti-cancer complexes.

Wheate NJ, Cullinane C, Webster LK, Collins JG.

Anticancer Drug Des. 2001 Apr-Jun;16(2-3):91-8.

PMID:
11962517
10.

Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.

Talarico T, Cullinane CM, Gray PJ, Webster LK, Deacon GB, Phillips DR.

Anticancer Drug Des. 2001 Apr-Jun;16(2-3):135-41.

PMID:
11962511
11.

Atypical pharmacokinetics and excretion of new platinum analogues in rodents.

Webster LK, Ellis AG, Apicella C, Deacon GB.

Cancer Chemother Pharmacol. 2002 Jan;49(1):87-92.

PMID:
11855757
12.

Pulse oximetry interference in paediatric neurosurgery.

Webster LK, Barry BN, Short JA.

Anaesthesia. 2002 Jan;57(1):83-4. No abstract available.

13.

Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.

Dooley MJ, Poole SG, Rischin D, Webster LK.

Eur J Cancer. 2002 Jan;38(1):44-51.

PMID:
11750838
14.

Synthesis, DNA binding and cytotoxicity of isohelical DNA groove binding platinum complexes.

Wheate NJ, Webster LK, Brodie CR, Collins JG.

Anticancer Drug Des. 2000 Oct;15(5):313-22.

PMID:
11354307
15.

High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma.

Ellis AG, Nice EC, Weinstock J, Levitzki A, Burgess AW, Webster LK.

J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):193-9.

PMID:
11318415
16.

A pharmacokinetic and phase II study of gallium nitrate in patients with non-small cell lung cancer.

Webster LK, Olver IN, Stokes KH, Sephton RG, Hillcoat BL, Bishop JF.

Cancer Chemother Pharmacol. 2000;45(1):55-8.

PMID:
10647502
17.

Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness.

Hambley TW, Battle AR, Deacon GB, Lawrenz ET, Fallon GD, Gatehouse BM, Webster LK, Rainone S.

J Inorg Biochem. 1999 Oct;77(1-2):3-12.

PMID:
10626347
18.

A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

Rischin D, Webster LK, Millward MJ, Toner GC, Nawaratne S, Ganju V, Francis P, Bishop JF.

Invest New Drugs. 1999;17(1):73-80.

PMID:
10555125
19.

Activity and DNA binding of new organoamidoplatinum (II) complexes.

Talarico T, Phillips DR, Deacon GB, Rainone S, Webster LK.

Invest New Drugs. 1999;17(1):1-15.

PMID:
10555118
20.

Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.

Ellis AG, Webster LK.

Cancer Chemother Pharmacol. 1999;43(1):13-8.

PMID:
9923536
21.

Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.

Baille P, Bruno R, Schellens JH, Webster LK, Millward M, Verweij J, Montay G.

Clin Cancer Res. 1997 Sep;3(9):1535-8.

22.

Phase I trial of cremophor EL with bolus doxorubicin.

Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.

Clin Cancer Res. 1998 Oct;4(10):2321-9.

23.

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C.

J Clin Oncol. 1997 Feb;15(2):750-8.

PMID:
9053501
24.

Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft.

Joschko MA, Webster LK, Bishop JF, Groves J, Yuen K, Olver IN, Narayan KN, Ball DL.

Cancer Chemother Pharmacol. 1997;40(6):534-9.

PMID:
9332470
25.

Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model.

Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ.

Radiat Oncol Investig. 1997;5(2):62-71.

PMID:
9303059
26.

Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.

Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Millward MJ.

Cancer Chemother Pharmacol. 1997;39(6):557-60.

PMID:
9118471
27.

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.

Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF.

J Natl Cancer Inst. 1996 Sep 18;88(18):1297-301.

PMID:
8797769
28.

Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.

Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R.

Aust N Z J Med. 1996 Jun;26(3):372-9.

PMID:
8811211
29.
30.

Anti-tumor activity, in vitro and in vivo, of some triphenylphosphinegold(i) thionucleobases.

Webster LK, Rainone S, Horn E, Tiekink ER.

Met Based Drugs. 1996;3(2):63-6.

31.

Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80.

Ellis AG, Crinis NA, Webster LK.

Cancer Chemother Pharmacol. 1996;38(1):81-7.

PMID:
8603456
32.

Plasma alcohol concentrations in patients following paclitaxel infusion.

Webster LK, Crinis NA, Morton CG, Millward MJ.

Cancer Chemother Pharmacol. 1996;37(5):499-501.

PMID:
8599876
33.

Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.

Webster LK, Ellis AG, Kestell P, Rewcastle GW.

Drug Metab Dispos. 1995 Mar;23(3):363-8.

PMID:
7628302
34.

A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin.

Olver IN, Webster LK, Millward MJ, Stokes KH, Bishop JF.

Cancer Chemother Pharmacol. 1995;37(1-2):79-85.

PMID:
7497601
35.
36.

In vitro antitumour activity of some triorganophosphinegold(i) thionucleobases.

Tiekink ER, Cookson PD, Linahan BM, Webster LK.

Met Based Drugs. 1994;1(4):299-304.

37.

Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(II) complexes with the potential to bind enantioselectively to DNA.

Vickery K, Bonin AM, Fenton RR, O'Mara S, Russell PJ, Webster LK, Hambley TW.

J Med Chem. 1993 Nov 12;36(23):3663-8.

PMID:
8246235
39.

Effect of toremifene on antipyrine elimination in the isolated perfused rat liver.

Webster LK, Ellis AG, Bishop JF.

Cancer Chemother Pharmacol. 1993;31(4):319-23.

PMID:
8422697
40.

cis-bis(pyridine)platinum(II) organoamides with unexpected growth inhibition properties and antitumor activity.

Webster LK, Deacon GB, Buxton DP, Hillcoat BL, James AM, Roos IA, Thomson RJ, Wakelin LP, Williams TL.

J Med Chem. 1992 Sep 4;35(18):3349-53.

PMID:
1527784
41.

Reversal of multidrug resistance by surfactants.

Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH.

Br J Cancer. 1992 Jul;66(1):62-8.

42.

A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Olver IN, Webster LK, Bishop JF, Stokes KH.

Cancer Chemother Pharmacol. 1992;29(5):354-60.

PMID:
1551173
43.

High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites.

Webster LK, Crinis NA, Stokes KH, Bishop JF.

J Chromatogr. 1991 Apr 19;565(1-2):482-7.

PMID:
1831461
44.

A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy.

Olver IN, Webster LK, Bishop JF, Clarke J, Hillcoat BL.

Eur J Cancer Clin Oncol. 1989 Oct;25(10):1457-61.

PMID:
2591437
45.

Effect of trimethoprim, paracetamol and cimetidine on trimetrexate metabolism by rat perfused isolated livers.

Webster LK, Tong WP, McCormack JJ.

J Pharm Pharmacol. 1987 Nov;39(11):942-4.

PMID:
2892922
46.

Influence of hypoxia on the metabolism and biliary excretion of trimetrexate by the isolated perfused rat liver.

Webster LK, McCormack JJ.

Biochem Pharmacol. 1986 Dec 15;35(24):4587-9. No abstract available.

PMID:
2947581
47.

Absence of histopathological response to cadmium in gill and digestive diverticula of the mussel, Mytilus edulis.

Giraud AS, Webster LK, Fabris JG, Collett LC, Yeomans ND.

Bull Environ Contam Toxicol. 1986 Jan;36(1):146-9. No abstract available.

PMID:
3940562
48.

Metabolism and biliary excretion of trimetrexate by the isolated perfused rat liver.

Webster LK, Tong WP, McCormack JJ.

Cancer Lett. 1985 Oct;29(1):65-71.

PMID:
2933139
49.

Influence of cimetidine and ranitidine on ethanol pharmacokinetics.

Webster LK, Jones DB, Smallwood RA.

Aust N Z J Med. 1985 Jun;15(3):359-60. No abstract available.

PMID:
3864432
50.

Effect of hypoxia on oxidative and reductive pathways of omeprazole metabolism by the isolated perfused rat liver.

Webster LK, Jones DB, Mihaly GW, Morgan DJ, Smallwood RA.

Biochem Pharmacol. 1985 Apr 15;34(8):1239-45.

PMID:
3994745

Supplemental Content

Loading ...
Support Center